Estratégias econômicas comportamentais e de pessoal para aumentar a adoção do pacote ABCDEF na UTI (BEST-ICU)
Estratégias econômicas comportamentais e de pessoal para aumentar a adoção do pacote ABCDEF na unidade de terapia intensiva (BEST UTI): um ensaio clínico randomizado controlado escalonado
The overarching goal of this study is to support the "real world" assessment of strategies used to foster adoption of several highly efficacious evidence-based practices in healthcare systems that provide care to critically ill adults with known health disparities. Investigators will specifically evaluate two discrete strategies grounded in behavioral economic and implementation science theory (i.e., real-time audit and feedback and registered nurse implementation facilitation) to increase adoption of the ABCDEF bundle in critically ill adults.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Millions of survivors of critical illness worldwide experience profound and frequently persistent physical, mental, and cognitive health impairments that are often preventable through the application of existing knowledge. These impairments are commonly acquired in the intensive care unit (ICU) and are often initiated and/or exacerbated by known racial and socioeconomic health disparities and outdated mechanical ventilation (MV) liberation and symptom management practices. Indeed, ICU-acquired pain, anxiety, delirium, and weakness are associated with numerous adverse health outcomes including prolonged MV, mortality, functional decline, new institutionalization, and severe neurocognitive dysfunction. A robust body of research demonstrates that clinical outcomes improve when integrated, interprofessional approaches to MV liberation and symptom management are applied early in the course of critical illness. One such approach is the ABCDEF bundle. When applied in everyday practice, ABCDEF bundle performance is consistently associated with meaningful improvements in important patient and healthcare system outcomes. Unfortunately, ABCDEF bundle performance remains unacceptably low as clinicians struggle with multiple barriers to bundle delivery.
Investigator's previous work demonstrates bundle-related clinical decision making is indeed complex and frequently influenced by prevailing ICU social norms, common knowledge deficits, and substantial workflow challenges. Missing from the literature are evidence-based implementation strategies that are adaptable, responsive to community needs, and account for the cultural and organizational factors necessary to increase bundle adoption particularly in traditionally under-resourced settings like safety net hospitals. Until this key gap in knowledge is filled, the excessively high morbidity, mortality, costs, and disparities associated with critical care delivery will continue and the public health benefit of the ABCDEF bundle will not be fully realized.
Congruent with NIH policy, the goal of this proposal is to support the "real world" assessment of strategies used to foster adoption of several highly efficacious evidence-based practices in healthcare systems that provide care to critically ill adults with known health disparities. Based on strong preliminary data, the study's overall objective is to evaluate two discrete strategies grounded in behavioral economic and implementation science theory to increase adoption of the ABCDEF bundle in critically ill adults. The strategies being evaluated target a variety of ICU team members and known behavioral determinants of ABCDEF bundle performance.
Investigators will conduct a 3-arm, pragmatic, stepped-wedge, cluster-randomized, trial to evaluate both implementation (primary) and clinical (secondary) effectiveness outcomes. After creating 6 matched pairs of 12 ICUs from 3 discrete safety net hospitals (estimated total N=16,500 patients on MV), they will randomly be assigned within each matched pair to receive either real-time audit and feedback or a Registered Nurse (RN) implementation facilitator and each pair to one of six wedges. At the end of the 27-month trial, implementation and clinical outcomes will collected for an additional 3 months to evaluate the effects of removing the implementation strategies.
Aim 1: Primary Implementation Objective: Compare the effectiveness of real-time audit and feedback and RN implementation facilitation on proportional ABCDEF bundle performance (primary study outcome).
Aim 1: Secondary Implementation Objective: Compare the effectiveness of real-time audit and feedback and RN implementation facilitation on complete ABCDEF bundle performance.
Aim 2: Primary Clinical Objective: Compare the effectiveness of real-time audit and feedback and RN implementation facilitation on duration of invasive mechanical ventilation.
Aim 2: Secondary Clinical Objective: Compare the effectiveness of real-time audit and feedback and RN implementation facilitation on other patient-centered outcomes (i.e., new tracheostomy placement; advanced non-invasive respiratory therapy use and duration; ICU, hospital, and 30-day mortality; ICU and hospital length of stay; ICU days with acute brain dysfunction (i.e., ICU delirium and/or coma); ICU physical restraint use; daily and total opioid, benzodiazepine, sedative/hypnotic, antipsychotic, melatonin receptor agonist, and paralytic medication use in ICU stay and at hospital discharge; ICU days with a family visit; discharge disposition; ICU readmission; physical therapy utilization in ICU and at hospital discharge; 30-day hospital readmission; ICU days with significant pain; unplanned extubations; reintubations within 24 hours of extubation; hospital-acquired thromboembolic disease, clinically significant falls acquired during hospitalization, hospital-acquired pressure ulcers).
Aim 3: Identify and describe key stakeholders' experiences with, and perspectives of, real-time audit and feedback and RN implementation.
Aim 3.1: Compare the effects of real-time audit and feedback and RN implementation on work intensity.
Aim 3.2: Compare the acceptability of real-time audit and feedback and RN implementation facilitation.
Aim3.3: Assess the association of work intensity with acceptability and proportional bundle performance.
Aim 3.4: Assess provider perspectives of barriers and facilitators to adoption of real-time audit and feedback and RN implementation.
Building on years of successful collaboration, investigator's experienced interprofessional team is ideally suited to perform the proposed work. Study results are expected to impact the field by developing equitable, efficient, effective, and replicable ways of accelerating the reliable uptake of the highly efficacious evidence-based ICU interventions contained in the ABCDEF bundle. This will dually address known healthcare disparities and ultimately improve the care and outcomes of millions of critically ill adults annually.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Michele C Balas, PhD, RN
- Número de telefone: (614) 949-5555
- E-mail: mibalas@unmc.edu
Estude backup de contato
- Nome: Eduard Vasilevskis, MD
- Número de telefone: (608) 261-1571
- E-mail: vasilevskis@wisc.edu
Locais de estudo
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa Hospitals and Clinics
-
Contato:
- Anna Krupp, PhD, RN
- Número de telefone: (319) 467-1902
- E-mail: anna-krupp@uiowa.edu
-
Contato:
- James Blum, MD
- Número de telefone: (319) 678-7116
- E-mail: james-blum@uiowa.edu
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- Recrutamento
- University of Nebraska Medical Center
-
Investigador principal:
- Breanna D Hetland, PhD
-
Subinvestigador:
- Chris S Wichman, PhD
-
Subinvestigador:
- James R Campbell, PhD
-
Subinvestigador:
- Ronnie Horner, PHD
-
Subinvestigador:
- Jungyoon Kim, PhD
-
Contato:
- Michele C Balas, PhD, RN
- Número de telefone: (402) 559-9758
- E-mail: mibalas@unmc.edu
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43201
- Recrutamento
- Ohio State University
-
Contato:
- Tony Gerlach, PHD
- Número de telefone: (614) 688-0234
- E-mail: anthony.gerlach@osumc.edu
-
Contato:
- Matthew Exline, MD
- Número de telefone: (614) 293-4925
- E-mail: matthew.exline@osumc.edu
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age > or = to 19 years at time of ICU admission
- Received invasive mechanical ventilation while in a cluster ICU
- Admitted to participating cluster ICU
- Cluster ICU length of stay of at least 24 hours
Exclusion Criteria:
- Patient who is admitted to the hospital who is already receiving chronic long-term mechanical ventilation from the home, assisted living, or long-term care setting
- Prisoners
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Sem intervenção: Usual care
Usual ICU care |
|
|
Experimental: Audit and Feedback
ICUs receive electronic dashboard that displays realtime ABCDEF bundle performance data |
ICUs randomized to this arm will receive and electronic dashboard that displays realtime ABCDEF bundle performance data |
|
Experimental: RN Implementation Facilitator
ICUs receive a extra RN who helps facilitate ABCDEF bundle implementation |
ICUs randomized to this arm will receive a RN who will assist with ABCDEF bundle implementation |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportional ABCDEF bundle performance
Prazo: 27 months
|
Defined as the percentage of eligible elements a patient receives on a given ICU day ["bundle dose"]. |
27 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Complete ABCDEF bundle performance
Prazo: 27 months
|
Defined as a patient day in which every eligible element of the bundle was performed (i.e., 100% of the bundle versus anything less; yes/no). |
27 months
|
|
Duration of invasive mechanical ventilation
Prazo: 27 months
|
Days spent in ICU on invasive mechanical ventilation |
27 months
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with new tracheotomy placement
Prazo: 27 months
|
Current Procedural Terminology code for tracheotomy during hospitalization |
27 months
|
|
advanced noninvasive respiratory therapy use and duration
Prazo: 27 months
|
The recorded timestamps for advanced non-invasive respiratory therapy using CPAP, BiLevel Positive Pressure Ventilation (BiPaP), or high flow cannula with oxygen flow rates >20 lpm using a face mask or other airway that is NOT an endotracheal tube will be monitored. Specific data elements in the EHR relevant to advanced non-invasive respiratory therapy will be examined. This may include.
Once the data is organized, the duration of advanced non-invasive respiratory therapy for each patient will be calculated using the following formula: Duration (in hours) = CPAP/BiPaP/High Flow Oxygen Initiation Time - CPAP/BiPaP/High Flow OxygenTermination Time |
27 months
|
|
Number of participants with an ICU mortality
Prazo: 27 months
|
A death event that is recorded in the electronic health record (EHR) that occurred after index ICU admission and prior to the index ICU discharge date and time |
27 months
|
|
Number of participants with a hospital mortality
Prazo: 27 months
|
A death event that is recorded in the EHR that occurred after index ICU admission and prior to discharge from the hospital on the index hospital stay. |
27 months
|
|
Number of participants who die within 30 days of hospital discharge
Prazo: 27 months
|
A death event that is recorded in the EHR that occurs within 30 days of the date of hospital discharge from the index hospital stay. |
27 months
|
|
ICU length of stay (LOS)
Prazo: 27 months
|
Date and time of ICU discharge minus the date and time of ICU admission. Each ICU stay will be recorded as unique ICU stays as a unique ICU encounter. |
27 months
|
|
hospital LOS
Prazo: 27 months
|
Date and time of hospital discharge minus the date and time of first encounter during the hospital encounter |
27 months
|
|
ICU days with acute brain dysfunction
Prazo: 27 months
|
Will record ICU days with delirium. A delirious day would include a 24-hour period with at least one Confusion Assessment Method ICU (CAM ICU) score that is measured as positive. The total would include the total number of days for which CAM ICU is measured to be positive. ICU coma days: Will record any day for which patients exhibit level of arousal scores consistent with coma (Richmond agitation/sedation score -4 or -5, Sedation agitation score of 1 or 2) and add the total number of coma days throughout any given ICU stay, and across all ICU stays within a hospitalization. |
27 months
|
|
ICU days with physical restraint use
Prazo: 27 months
|
Physical restraint status codes will be identified using the International Classification of Disease code Z78.1 "physical restraint status". |
27 months
|
|
Opioid, benzodiazepine, sedative/hypnotic, and antipsychotic medication use in ICU and at hospital discharge
Prazo: 27 months
|
Opioid, benzodiazepine, sedative/hypnotic, antipsychotic medication, and melatonin receptor agonist medication use in ICU and at hospital discharge as recorded in EHR |
27 months
|
|
Discharge destination
Prazo: 27 months
|
Will review hospital discharge destination coded as home, home with home health, short term skilled nursing facility, long term nursing facility, acute rehabilitation hospital, long-term acute care hospital, hospice, acute care hospital, death. |
27 months
|
|
Number of participants with an ICU readmission
Prazo: 27 months
|
Will be coded yes if a patient has at least one readmission to any ICU following discharge from the index ICU stay. |
27 months
|
|
Number of participants with 30 day hospital readmission
Prazo: 27 months
|
Coded yes if a patient has at least one hospital readmission following discharge from the index hospital stay. Importantly, will only be able to track same-hospital readmissions. |
27 months
|
|
Number of participants with physical therapy use in ICU and post discharge
Prazo: 27 months
|
Will collect data regarding daily interactions with physical therapy. |
27 months
|
|
Days with significant pain
Prazo: 27 months
|
Will define an ICU Day as having an episode of significant pain if any of the below are documented; Numeric rating score: A score of > 7 will be considered significant pain; critical care pain observation tool: A score > 2 will be considered significant pain; Behavioral pain scale: A score > 5 will be considered significant pain; Defense and Veterans Pain Rating Scale: A score > 4 will be considered significant pain; Pain in Alzheimer Disease score: A score > 4 will be considered significant pain |
27 months
|
|
Number of participants with a reintubation within 24 hours of extubation
Prazo: 27 months
|
Will assess for evidence of an order for intubation that occurs < 24 hours following evidence of extubation, or a prior order for extubation. |
27 months
|
|
Number of participants with an unplanned extubation
Prazo: 27 months
|
Will assess for evidence of extubations that do not follow provider orders for an extubation and/or are charted as unordered. |
27 months
|
|
Number of participants with hospital acquired thromboembolic disease
Prazo: 27 months
|
Will query for International Classification of Disease codes associated with thromboembolic disease. Diagnosis codes must be a secondary diagnosis code / hospital acquired |
27 months
|
|
Number of participants with a hospital acquired fall with injury
Prazo: 27 months
|
Will record fall and trauma coding consistent with the Center for Medicare Services Health Acquired Conditions specification for fracture, dislocation, and intracranial injury. |
27 months
|
|
Number of participants with a hospital acquired pressure ulcer
Prazo: 27 months
|
The codes for hospital acquired pressure ulcer will be consistent with the Center for Medicare Services Hospital Acquired Conditions coding. |
27 months
|
|
ICU days with family visit
Prazo: 27 months
|
Electronic health record documentation of family visit that occurred during ICU stay |
27 months
|
|
work intensity
Prazo: 27 months
|
6 item National Aeronautics and Space Administration Task Load Index; Higher scores indicate higher work intensity |
27 months
|
|
acceptability
Prazo: 27 months
|
4 item Acceptability of Intervention Measure; higher scores indicate greater acceptability |
27 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Michele C Balas, PhD, RN, University of Nebraska
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 0794-23-FB
- 1UG3HL165740-01A1 (Concessão/Contrato do NIH dos EUA)
- 4UH3HL165740-02 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
To support study replication and extension, all scientific data including operations and clinical data necessary for replication of this project will be made available in de-identified form before publication, or by the end of the funded period (whichever comes first) in an appropriate online repository. Data used for analysis will be stored in comma-separated values file format to aid in the reuse of collected and analyzed data. Both clinical locations and patient information will be de-identified. All HIPAA identifiers will be removed and low counts will be masked as well. Original data will be maintained at the principal investigator's institution . There will be no restriction to sharing the data.
Prazo de Compartilhamento de IPD
To support study replication and extension, all scientific data including operations and clinical data necessary for replication of this project will be made available in de-identified form before publication, or by the end of the funded period (whichever comes first) in an appropriate online repository. Data used for analysis will be stored in comma separated values format to aid in the reuse of collected and analyzed data. Both clinical locations and patient information will be de-identified. All HIPAA identifiers will be removed and low counts will be masked. Original data will be maintained at the principal investigator's institution . There will be no restriction to sharing the data.
Critérios de acesso de compartilhamento IPD
To support study replication and extension, all scientific data, including operational and clinical data necessary for replicating this project, will be made available in de-identified form before publication, or by the end of the funded period (whichever comes first), in an appropriate online repository. Data used for analysis will be stored in comma-separated values format to aid in the reuse of collected and analyzed data. Both clinical locations and patient information will be de-identified. All HIPAA identifiers will be removed and low counts will be masked. Original data will be maintained at the principal investigator's institution. There will be no restriction to sharing the data.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .